Compare · BRKR vs PKI
BRKR vs PKI
Side-by-side comparison of Bruker Corporation (BRKR) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- PKI is the larger of the two at $21.38B, about 3.8x BRKR ($5.60B).
- BRKR has hit the wire 12 times in the past 4 weeks while PKI has been quiet.
- BRKR has more recent analyst coverage (21 ratings vs 17 for PKI).
- Company
- Bruker Corporation
- PerkinElmer Inc.
- Price
- $36.77+0.12%
- $115.23-0.88%
- Market cap
- $5.60B
- $21.38B
- 1M return
- +1.96%
- -
- 1Y return
- -9.15%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 21
- 17
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
PerkinElmer Inc.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest BRKR
- Bruker Corporation filed SEC Form 8-K: Other Events
- Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
- Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
- Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
- Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
- SEC Form 4 filed by Munch Mark
- Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
- SEC Form DEFA14A filed by Bruker Corporation
- SEC Form DEF 14A filed by Bruker Corporation
- SEC Form 3 filed by new insider Bernard Thierry
Latest PKI
- Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)
- Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Klobuchar Michael A was granted 481 shares (SEC Form 4)
- Vandebroek Sophie V. was granted 481 shares (SEC Form 4)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- Singh Prahlad R. exercised 57,039 shares at a strike of $76.83, sold $2,212,480 worth of shares (21,217 units at $104.28) and covered exercise/tax liability with 15,424 shares, increasing direct ownership by 25% to 103,414 units (SEC Form 4)
- Victor Miriame exercised 2,408 shares at a strike of $105.62 and covered exercise/tax liability with 1,030 shares, increasing direct ownership by 15% to 10,470 units (SEC Form 4)